-
CSCO 2024 | Learning from the Past to Guide the Future: How Biomarker Testing Supports Precision Treatment for Lung Cancer
The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology and the Beijing Health Management Development Foundation, took place in Xiamen from September 25-29, 2024. During the conference, several lung cancer-focused forums highlighted cutting-edge research and progress in the field both domestically and internationally. During the…
-
ESMO 2024丨Docetaxel Remains Standard Therapy for PD-(L)1 Resistant Advanced NSCLC Patients
Anti-PD-(L)1 therapies have been approved for treating advanced non-small cell lung cancer (NSCLC). However, due to limited options, most patients experience disease progression while on anti-PD-(L)1 therapy. At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, Dr. Pascale Tomasini from the Multidisciplinary Oncology and Therapeutic Innovations department in Marseille, France, presented findings from…
-
IFSC 2024 | Dr. Daniel G.Tenen from the Cancer Science Institute of Singapore Decodes SALL4 Protein and Cancer
The 9th International Forum on Stem Cells (IFSC) in 2024 focuses on basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines, gathering experts and scholars from around the world to discuss the latest frontiers in scientific discoveries and technological advancements. During the conference, “Hematology Frontier” specially invited Dr. Daniel…
-
IFSC 2024 | Dr. Simón Méndez-Ferrer Shares New Strategies for the Regulation of the Bone Marrow Microenvironment and the Treatment of Myeloid Malignan
The 9th International Forum on Stem Cells (IFSC) in 2024 focuses on basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines, gathering experts and scholars from around the world to discuss the latest frontiers of scientific discoveries and technological advancements. During the conference, “Hematology Frontier” specially invited Dr. Simón…
-
IFSC 2024 | Dr. Rafael Bejar Unveils Clonal Hematopoiesis: Concepts, Risks, and New Treatment Strategies
The 9th International Forum on Stem Cells (IFSC) in 2024 focused on basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines, gathering experts and scholars from around the world to discuss the latest frontiers of scientific discoveries and technological advancements. During the conference, “Hematology Frontier” specially invited Dr. Rafael…
-
Academician Binghe Xu: The Rise of International Collaboration and China’s Role in Breast Cancer Clinical Research
With breast cancer incidence rates on the rise globally, it has become a major health threat to women. In China, the challenge of breast cancer control is equally significant, and improving the quality of diagnosis, treatment, and survival rates for breast cancer patients has become a critical task in healthcare. International cooperation has been a…
-
ESMO 2024丨Antibody-Drug Conjugates (ADCs) Offer Hope for Breast Cancer Patients, Including Those with Brain Metastases
Antibody-drug conjugates have expanded treatment options for patients with unresectable locally advanced or metastatic breast cancer, providing new options for those who have exhausted other treatments. Studies presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) aimed to expand the current use of ADCs to a wider patient population and…
-
ESMO 2024丨Early Immunotherapy Significantly Extends Overall Survival in Triple-Negative Breast Cancer Patients
The final results of the KEYNOTE-522 trial confirm the potential of pembrolizumab to change patient management, though careful patient selection and toxicity monitoring are essential.
Connecting Medical Expertise through Media